Eli Lilly and Company (LLY) Rating Lowered to Neutral at Credit Suisse Group

Eli Lilly and Company (NYSE:LLY) was downgraded by analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a report released on Tuesday, MarketBeat reports. They currently have a $88.00 target price on the stock, up from their previous target price of $84.23. Credit Suisse Group’s target price indicates a potential upside of 1.09% from the stock’s current price.

Several other research analysts also recently weighed in on the company. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the stock a “hold” rating in a research note on Friday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Cowen and Company restated a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a research note on Wednesday, October 4th. BMO Capital Markets reaffirmed a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a report on Monday, September 11th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and an average target price of $88.52.

Shares of Eli Lilly and (NYSE LLY) traded down 1.28% during midday trading on Tuesday, reaching $85.94. 2,145,076 shares of the company were exchanged. The company has a 50 day moving average price of $82.49 and a 200-day moving average price of $82.14. The stock has a market capitalization of $90.67 billion, a P/E ratio of 37.19 and a beta of 0.34. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the company posted $0.86 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/10/10/eli-lilly-and-company-lly-downgraded-by-credit-suisse-group-to-neutral.html.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 990,000 shares of company stock worth $82,949,650. Insiders own 0.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Acrospire Investment Management LLC grew its position in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and during the 2nd quarter worth $128,000. San Francisco Sentry Investment Group CA bought a new position in shares of Eli Lilly and during the 2nd quarter worth $129,000. Heritage Trust Co bought a new position in shares of Eli Lilly and during the 1st quarter worth $135,000. Finally, Point72 As

Several other research analysts also recently weighed in on the company. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the stock a “hold” rating in a research note on Friday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Cowen and Company restated a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a research note on Wednesday, October 4th. BMO Capital Markets reaffirmed a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a report on Monday, September 11th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and an average target price of $88.52.

Shares of Eli Lilly and (NYSE LLY) traded down 1.28% during midday trading on Tuesday, reaching $85.94. 2,145,076 shares of the company were exchanged. The company has a 50 day moving average price of $82.49 and a 200-day moving average price of $82.14. The stock has a market capitalization of $90.67 billion, a P/E ratio of 37.19 and a beta of 0.34. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the company posted $0.86 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/10/10/eli-lilly-and-company-lly-downgraded-by-credit-suisse-group-to-neutral.html.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 990,000 shares of company stock worth $82,949,650. Insiders own 0.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Acrospire Investment Management LLC grew its position in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and during the 2nd quarter worth $128,000. San Francisco Sentry Investment Group CA bought a new position in shares of Eli Lilly and during the 2nd quarter worth $129,000. Heritage Trust Co bought a new position in shares of Eli Lilly and during the 1st quarter worth $135,000. Finally, Point72 Asia Hong Kong Ltd grew its position in shares of Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares in the last quarter. 75.72% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply